

●▶ **Rocket Pharma**

(FDA, Approval)

Rocket Pharma obtains FDA approval for KRESLADI, an autologous hematopoietic stem cell-based gene therapy to treat pediatric patients with severe leukocyte adhesion deficiency-I

●▶ **Denali Therapeutics**

(FDA, Approval)

FDA grants approval to Denali Therapeutics' AVLAYAH, an enzyme replacement therapy to treat the neurologic manifestations of Hunter syndrome

●▶ **Corcept Therapeutics**

(FDA, Approval)

Corcept Therapeutics gets FDA approval for LIFYORLI plus nab-paclitaxel to treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior systemic treatment regimens

●▶ **Gedeon Richter**

(EU, Approval)

EC grants approval to Gedeon Richter's FYLREVY as a hormone replacement therapy for oestrogen deficiency symptoms in non-hysterectomised postmenopausal women



●► **Henlius**

(Health Canada, Approval)

Health Canada approves Henlius' BILDYOS injection 60 mg/mL, a PROLIA biosimilar and TUZEMTY injection 120 mg/1.7 mL, a XGEVA biosimilar for all indications of the reference products

●► **UCB**

(CHMP, Positive Opinion)

CHMP issues a positive opinion on UCB's ZILBRYSQ pre-filled pen, a subcutaneous C5 inhibitor for the treatment of generalized myasthenia gravis

●► **Sanofi**

(CHMP, Positive Opinion)

Sanofi's Sarclisa subcutaneous on-body injector formulation receives positive CHMP opinion for the treatment of multiple myeloma

●► **Sandoz**

(Launch)

Sandoz launches azelastine and fluticasone fixed-dose-combination nasal spray in Germany and Switzerland for the relief of symptoms in moderate to severe seasonal allergic rhinitis in adults



●► **Biocytogen**

(Collaboration)

Biocytogen Pharmaceuticals collaborates strategically with Moonlight Bio to advance the development of cutting-edge cell therapies for difficult-to-treat cancers

●► **Quotient Therapeutics**

(Collaboration)

Quotient Therapeutics has entered a multi-year collaboration with Merck to research novel drug targets for inflammatory bowel disease using proprietary somatic genomics platform

●► **Gedeon Richter**

(Collaboration)

Gedeon Richter collaborates with Fuji Pharma for the development of women's health product candidates, where Fuji will obtain rights to develop, manufacture and commercialize in Japan, ASEAN countries and South Korea

●► **Pfizer**

(Phase 3, Results)

Pfizer and Valneva's vaccine candidate LB6V demonstrates more than 70% efficacy in the Phase 3 VALOR trial in preventing Lyme disease, with no safety concerns



●▶ **Takeda**

(Phase 3, Results)

Takeda's Phase 3 Latitude PsO 3001 and Latitude PsO 3002 trials evaluating TAK-279 met both primary endpoints at Week 16, achieving a 75% improvement from baseline in PASI when compared to placebo

●▶ **AstraZeneca**

(Phase 3, Results)

AstraZeneca's tozorakimab met its endpoints in the OBERON and TITANIA Phase 3 trials for moderate-to-severe chronic obstructive pulmonary disease compared to placebo, with significant improvements in lung function

●▶ **Sanofi**

(Phase 3, Results)

Sanofi's three Phase 3 trials - COAST 1, COAST 2 and SHORE met their primary and key secondary endpoints evaluating amlitelimab, showing improvements in skin clearance and disease severity compared to placebo

